New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
05:58 EDTAZN, PStocks with implied volatility movement; P AZN
Stocks with implied volatility movement; Pandora (P) 58, AstraZeneca (AZN) 32 according to iVolatility.
News For P;AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2015
19:06 EDTPOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 17.2%... Marketo (MKTO), up 15.4%... Juniper Networks (JNPR), up 9.9%... NetGear (NTGR), up 9.2%... Qlik Technologies (QLIK), up 9.1%... LogMeIn (LOGM), up 9.9%... Pandora (P), up 10.3%... Mitek Systems (MITK), up 7.8%... Proofpoint (PFPT), up 5.1%... Supreme Industries (STS), up 4.7%... Skyworks (SWKS), up 3.6%... IGI Laboratories (IG), up 3.7%... Maxim Integrated Products (MXIM), up 4.1%... Boyd Gaming (BYD), up 4.1%... Trinity Industries (TRN), up 5%... Trinity Industries (N), up 3.2%... Starbucks (SBUX), up 4.5%. ALSO HIGHER: Qorvo (QRVO), up 2.7% after Skyworks reported quarterly results. DOWN AFTER EARNINGS: TrueCar (TRUE), down 33.1% after reporting quarterly results and cutting fiscal 2015 revenue guidance... Tripadvisor (TRIP), down 9.2%... Align Technology (ALGN), down 7.4%... Capital One (COF), down 4.9%... PMC-Sierra (PMCS), down 9.1%... athenahealth (ATHN), down 2.1%. ALSO LOWER: Sunesis Pharmaceuticals (SNSS), down 59.7% after giving vosaroxin regulatory update... Avalanche Biotechnologies (AAVL), down 5.6% after CEO Thomas Chalberg, Jr., Ph.D. resigns and Hans Hull name interim CEO.
16:16 EDTPPandora reports Q2 adjusted EPS 5c, consensus 2c
Subscribe for More Information
16:10 EDTPPandora sees FY15 revenue $1.175B-$1.185B, consensus $1.17B
Sees FY15 adjusted EBITDA $75M-$85M. Sees tax rate 30%-35%.
16:08 EDTPPandora rallies sharply, levels to watch
Subscribe for More Information
16:08 EDTPPandora sees Q3 revenue $310M-$315M, consensus $309.2M
Subscribe for More Information
16:07 EDTPPandora reports total Q2 RPMs up 24% to $53.91
Subscribe for More Information
15:04 EDTPNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTPPandora has reached attractive entry point, says Oppenheimer
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
July 15, 2015
17:00 EDTAZNInnerWorkings to provide AstraZeneca exclusive marketing execution
InnerWorkings (INWK), the leading marketing execution firm, has become the exclusive North American marketing execution partner of AstraZeneca (AZN). Under the seven-year agreement, InnerWorkings will manage AstraZeneca’s marketing print operations across North America, which will improve AstraZeneca’s transparency and reporting as well as strengthen its brand impact. Strategically placed across the U.S., InnerWorkings’ three onsite teams based in Delaware, Maryland, and Pennsylvania will help AstraZeneca sharpen its financial visibility, unify its brands, and enhance its marketing effectiveness. By tapping InnerWorkings’ $1B-dollar buying power, AstraZeneca will gain vital insights, promote sustainability, and refine its marketing spend.
09:34 EDTPPandora downgraded to Mixed from Positive at OTR Global
Subscribe for More Information
06:03 EDTPStocks with implied volatility above IV index mean; P HLF
Subscribe for More Information
July 14, 2015
05:59 EDTPStocks with implied volatility above IV index mean; P HLF
Subscribe for More Information
July 13, 2015
15:52 EDTAZNQIAGEN companion diagnostic wins FDA approval for use with Iressa
Subscribe for More Information
13:33 EDTAZNFDA approves AstraZeneca metastatic lung cancer treatment
Subscribe for More Information
11:47 EDTAZNFDA approves new drug to treat schizophrenia
The U.S. FDA announced that it has approved Rexulti tablets to treat adults with schizophrenia and as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder. Rexulti is manufactured by Tokyo-based Otsuka Pharmaceutical. Novartis' (NVS) Clozaril is indicated to treat severely ill adult patients with schizophrenia who have not responded appropriately to standard antipsychotic treatment. Other atypical antipsychotics include Otsuka's Abilify, Pfizer's (PFE) Geodon, Janssen's (JNJ) Invega and Risperdal, Forest Labs' (ACT) Saphris, AstraZeneca's (AZN) Seroquel and Eli Lilly's (LLY) Zyprexa.
07:44 EDTAZNEli Lilly price target raised to $105 from $100 at Jefferies
Subscribe for More Information
05:59 EDTPStocks with implied volatility above IV index mean; P HLF
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use